Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia.
Adolescent
Adult
Aged
Aged, 80 and over
Antibiotics, Antitubercular
/ pharmacology
Drug Resistance, Multiple, Bacterial
/ genetics
Female
Genotype
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Diagnostic Techniques
/ instrumentation
Mycobacterium tuberculosis
/ classification
Reagent Kits, Diagnostic
/ standards
Rifampin
/ pharmacology
Tuberculosis, Multidrug-Resistant
/ diagnosis
Tunisia
Whole Genome Sequencing
Young Adult
Fluoroquinolones
GenoType MTBDRsl V2.0
MGIT 960
Second-line injectable drugs
XDR-TB
Journal
Research in microbiology
ISSN: 1769-7123
Titre abrégé: Res Microbiol
Pays: France
ID NLM: 8907468
Informations de publication
Date de publication:
Historique:
received:
27
08
2020
revised:
06
02
2021
accepted:
09
03
2021
pubmed:
20
3
2021
medline:
25
2
2023
entrez:
19
3
2021
Statut:
ppublish
Résumé
Rapid detection of the second-line drug (SLD) resistant tuberculosis (TB) strains is challenging to prescribe an immediate adequate treatment and limit the transmission of SLD resistant strains. The study aimed to evaluate the performance of GenoType MTBDRsl V2.0 compared to phenotypic drug susceptibility testing (pDST:MGIT960) to detect resistance to SLD of Mycobacterium tuberculosis (MTB) isolates in Tunisia, between May 2015 and December 2019. As a matter of fact, 103 rifampicin-resistant and multidrug-resistant MTB strains were included. Discrepancies between pDST and MTBDRsl were solved by whole genome sequencing. Compared to pDST, MTBDRsl V2.0 showed a sensitivity of 92.8% (68.5%-98.7%) in detecting resistance to fluoroquinolones. As for second-line injectable drugs, it presented a sensitivity of 80.0% (49.0%-94.3%). MTBDRsl had sensitivities of 100.0% (67.5%-100.0%), 75.0% (40.9%-92.8%) and 100.0% (60.9%-100.0%) respectively for kanamycin, capreomycin and amikacin. The specificity was 100.0% for all the drugs evaluated. As for diagnosing XDR-TB, it had a sensitivity of 57.1% (25.0%-84.1%) and a specificity of 100.0% (96.1%-100.0%). MTBDRsl V2.0 showed a high performance in detecting SLD resistance with a short turnaround time compared with pDST, which made it possible to start an early treatment and to maintain a low prevalence of SLD resistance and XDR-TB in Tunisia.
Identifiants
pubmed: 33737037
pii: S0923-2508(21)00030-9
doi: 10.1016/j.resmic.2021.103816
pii:
doi:
Substances chimiques
Antibiotics, Antitubercular
0
Reagent Kits, Diagnostic
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103816Informations de copyright
Copyright © 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no competing interests.